valine and Histiocytosis, Langerhans-Cell

valine has been researched along with Histiocytosis, Langerhans-Cell in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abdel-Wahab, O; Arcila, ME; Baselga, J; Blay, JY; Chau, I; Diamond, EL; Durham, B; Elez, E; Erinjeri, JP; Hyman, DM; Lacouture, M; Lockhart, AC; Makrutzki, M; Martínez-Valle, F; Pitcher, B; Puzanov, I; Raje, NS; Riehl, T; Subbiah, V; Torrisi, J; Ulaner, G; Wolf, J	1
Betz, BL; Brown, NA; Elenitoba-Johnson, KS; Furtado, LV; Kiel, MJ; Lim, MS; Weigelin, HC	1
Amoura, Z; Arnaud, L; Benameur, N; Besnard, S; Charlotte, F; Cluzel, P; Cohen-Aubart, F; Donadieu, J; Drier, A; Emile, JF; Haroche, J; Hervier, B; Maksud, P	1

Trials

1 trial(s) available for valine and Histiocytosis, Langerhans-Cell

Article	Year
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3 Topics: Aged; Amino Acid Substitution; Erdheim-Chester Disease; Female; Fluorodeoxyglucose F18; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Mutation, Missense; Positron Emission Tomography Computed Tomography; Prognosis; Proto-Oncogene Proteins B-raf; Survival Analysis; Treatment Outcome; Valine; Vemurafenib	2018

Article

Year

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3

Topics: Aged; Amino Acid Substitution; Erdheim-Chester Disease; Female; Fluorodeoxyglucose F18; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Mutation, Missense; Positron Emission Tomography Computed Tomography; Prognosis; Proto-Oncogene Proteins B-raf; Survival Analysis; Treatment Outcome; Valine; Vemurafenib

2018

Other Studies

2 other study(ies) available for valine and Histiocytosis, Langerhans-Cell

Article	Year
High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood, 2014, Sep-04, Volume: 124, Issue:10 Topics: Amino Acid Substitution; Female; Gene Frequency; Genetic Predisposition to Disease; Glutamic Acid; Histiocytosis, Langerhans-Cell; Humans; Male; MAP Kinase Kinase 1; Mutation, Missense; Prevalence; Proto-Oncogene Proteins B-raf; Retrospective Studies; Valine	2014
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, Feb-28, Volume: 121, Issue:9 Topics: Adult; Aged; Amino Acid Substitution; Anti-Inflammatory Agents; Drug Resistance; Erdheim-Chester Disease; Female; Glutamic Acid; Histiocytosis, Langerhans-Cell; Humans; Indoles; Male; Middle Aged; Mutation, Missense; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Valine; Vemurafenib	2013

Article

Year

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Blood, 2014, Sep-04, Volume: 124, Issue:10

Topics: Amino Acid Substitution; Female; Gene Frequency; Genetic Predisposition to Disease; Glutamic Acid; Histiocytosis, Langerhans-Cell; Humans; Male; MAP Kinase Kinase 1; Mutation, Missense; Prevalence; Proto-Oncogene Proteins B-raf; Retrospective Studies; Valine

2014

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.

Blood, 2013, Feb-28, Volume: 121, Issue:9

Topics: Adult; Aged; Amino Acid Substitution; Anti-Inflammatory Agents; Drug Resistance; Erdheim-Chester Disease; Female; Glutamic Acid; Histiocytosis, Langerhans-Cell; Humans; Indoles; Male; Middle Aged; Mutation, Missense; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Valine; Vemurafenib

2013